Considerations for Extended Chemoimmunotherapy

Dr. Sabari discusses how, for extensive stage small cell lung cancer (ES-SCLC) that progresses within six months after platinum-based chemoimmunotherapy and immunotherapy maintenance, options like lurbinectedin, topotecan, and irinotecan are considered viable subsequent treatments due to their proven effectiveness in similar clinical scenarios.

EP: 1.Clinical Impressions and Therapy Goals

Now Viewing

EP: 2.Considerations for Extended Chemoimmunotherapy

EP: 3.Prophylactic Cranial Irradiation Considerations

EP: 4.Mechanism of Action of BiTE Immunotherapy

EP: 5.Interpreting DeLLphi-301 Trial Results: ORR, Duration of Response, and Long-Term Outcomes

EP: 6.Significance of Durable Responses in DeLLphi-301 Trial

EP: 7.Expectations for PFS and OS in Relapsed/Refractory SCLC

EP: 8.Future Potential in Combination Therapies

EP: 9.Dual Maintenance With BiTE and PD-L1 Inhibitors

EP: 10.B7-H3 Mechanism and Therapeutic Potential

EP: 11.Current Practices in B7-H3 Testing

EP: 12.Interpreting IDeate-Lung02 Trial Outcomes

EP: 13.Comparing Dosing Schedules With Standard Therapies

EP: 14.Potential Synergies With T-Cell Engagers

EP: 15.Prospects in First-Line and Maintenance Settings

EP: 16.Mechanism of Action Compared With Other Alkylating Agents

Video content above is prompted by the following:

In the case of ES-SCLC that progresses in less than 6 months after a second course of m-based chemoimmunotherapy + IO maintenance, what other treatment options,in the absence of a clinical trial, would you consider as a subsequent line of therapy, and why?

Recent Videos